InterMune (ITMN) Reports Smaller-Than-Expected Loss; Guides In-line
ITMN Hot Sheet
Revenue Growth %: +40.2%Financial Fact:
Collaboration revenue: 0
Today's EPS Names:
CMRG, LONG, IMOS, More
InterMune Inc (NASDAQ: ITMN) reports a Q3 loss of $0.19, 2 cents better than the analyst estimate of ($0.21). Revenue for the quarter was $23.3 million, which compares to the estimate of $26.70 million.
Revenue: 2009 revenue, including Actimmune® and milestone payments from Roche, is expected to be in a range of approximately $45 to $50 million. Actimmune revenue represents approximately 50 percent of this revenue range. (Consensus is $48.02 million)
Revenue: 2009 revenue, including Actimmune® and milestone payments from Roche, is expected to be in a range of approximately $45 to $50 million. Actimmune revenue represents approximately 50 percent of this revenue range. (Consensus is $48.02 million)
You May Also Be Interested In
- UPDATE: Youku.com (YOKU) Misses Q1 EPS by 1c; Sees Q2 Sales Up 90-100% YoY
- Shoe Carnival, Inc. (SCVL) Tops Q1 EPS by 3c; Issues Mixed Guidance
- Pacific Sunwear Of California (PSUN) Tops Q1 EPS by 9c; Guides In-line
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
